People at Risk for Alzheimer’s Wanted for Major Study Testing Possible Preventive Therapies

People at Risk for Alzheimer’s Wanted for Major Study Testing Possible Preventive Therapies
Older people — ages 60 to 75 — in good cognitive health but with two copies of the "risk gene" for Alzheimer’s disease (AD) are being asked to take part in Generation Study, a collaborative and global research project investigating treatments that might stop the disease from developing. Two copies of the APOE4 gene are inherited, one from each parent, and people who meet age and health requirements but do not know of their genetic risk status can ask that it be determined by joining the Gene Match Program, run by led by the Banner Alzheimer’s Institute. Some may then be invited to take part in the study. Generation Study will test the potential of two investigative therapies against placebo in preventing amyloid beta build-up in the brain, which is thought to be associated with Alzheimer's development. Some 90 worldwide institutions — in the U.S., Canada, Australia and across Europe — are involved (those in the U.S. can be found here). Banner Alzheimer’s Institute, based in Arizona, is running the trial with Novartis, which is providing the drugs to be tested, CAD106 (a vaccine therapy) and CNP520 (an oral treatment), and Amgen, which helped develop CNP520. Both are designed to reduce amyloid beta accumulation in the b
Subscribe or to access all post and page content.

One comment

  1. Brad Sparks says:

    If you’re serious about treating and likely preventing Alzheimer’s, as well as Parkinson’s, MS, ALS and other neurodegenerative diseases, then start supporting and funding that trial activities of Anavex Life Sciences. Its approach is more upstream, actually addressing the cause of these CNS disorders: neurodegeneration. By properly modulating Sigma-1 and Muscarinic receptors, cellular homeostasis can be restored. All patients from the Phase 2a trial have stabilized and many are better than when they began, returning to playing the piano, oil painting, golfing and simple daily living. Anavex’s Phase 2b/3 trial is about to commence and will only require 300 patients.

    Anavex’s SigmaCeptor drug platform will no doubt be the leader in a whole new generation of drugs designed to maintain cellular balance and treating/preventing a multitude of CNS disorders.

Leave a Comment

Your email address will not be published. Required fields are marked *